NCT01617928View on ClinicalTrials.gov

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Solid Tumors
Interventions
DRUG

veliparib (ABT-888)

Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.

DRUG

carboplatin

Carboplatin will be administered on Day 3 of each cycle, intravenously.

DRUG

paclitaxel

Paclitaxel will be administered on Day 3 of each cycle, intravenously.

Trial Locations (1)

Unknown

Site Reference ID/Investigator# 68622, Tokyo

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01617928 - A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors | Biotech Hunter | Biotech Hunter